A Phase 1b/2 Study of Duvelisib in Combination With FCR (DFCR) for Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, MMSc1, David C. Fisher, MD1, Svitlana Tyekucheva, PhD2, Mikaela McDonough1, John Hanna1, Brandon Lee1, Karen Francoeur, RN1, Josie Montegaard, NP1, Oreofe Odejide, MD1, Philippe Armand, MD, PhD1, Jon Arnason, MD3, Jennifer R. Brown, MD, PhD1

1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
2Department of Data Sciences, DFCl and Department of Biostatistics Harvard T.H. Chan School of Public Health
3Dept. of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, USA

Abstract

Fludarabine, cyclophosphamide, rituximab (FCR) is highly effective initial therapy for younger patients with chronic lymphocytic leukemia (CLL); however, most eventually relapse. Duvelisib is a delta/gamma PI3K inhibitor approved for relapsed/refractory CLL. We conducted an investigator-initiated, phase 1b/2 study of duvelisib + FCR (DFCR) as initial treatment for CLL patients aged ≤65. A standard 3+3 design included 2 dose levels of duvelisib (25 mg qd and 25 mg bid). Duvelisib was given for 1 week, then with standard FCR added for up to six 28-day cycles, then up to 2 years of duvelisib maintenance. Thirty-two patients were enrolled. The phase 2 dose of duvelisib was identified as 25 mg bid. Hematologic toxicity was common, and all-grade nonhematologic toxicities included transaminitis (28%), febrile neutropenia (22%), pneumonia (19%), and colitis (6%). The best overall response rate by ITT was 88% (56% CR/CRi, 32% PR). The best rate of bone marrow undetectable minimal residual disease (BM-uMRD) by ITT was 66%. The rate of CR with BM-uMRD at end of combination treatment (primary endpoint) was 25%. Three-year PFS and OS are 73% and 93%, respectively. DFCR is active as initial therapy of younger CLL patients. Immune-mediated and infectious toxicities occurred and required active management.

INTRODUCTION

Until recently, chemoimmunotherapy was considered to be the standard of care for most patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in need of frontline therapy. Over the last several years, novel-agent–based approaches have been approved for the frontline treatment of CLL, including inhibitors of Bruton tyrosine...
kinase given with or without anti-CD20 monoclonal antibodies,\textsuperscript{1–3} as well as the BCL-2 inhibitor venetoclax given with obinutuzumab.\textsuperscript{4} These agents have been particularly useful for elderly patients and those with comorbidities, who do not tolerate chemoimmunotherapy as well, and also for patients with higher risk forms of CLL, such as those with TP53 aberrant disease, who do not typically respond durably to chemoimmunotherapy. Despite the efficacy of novel agent therapy, it remains unknown whether this approach to frontline CLL therapy will provide long-term, treatment-free remission. While cure may not be needed for the majority of CLL patients who are elderly with comorbidities, and may be better served by strategies to control disease and minimize toxicity, a smaller group of young, fit CLL patients may be interested in pursuing more aggressive time-limited therapy with the potential for long-term disease-free survival.

To date, the only therapy outside of allogeneic transplantation that has shown curative potential in CLL is the chemoimmunotherapy regimen fludarabine, cyclophosphamide, rituximab (FCR), based on long-term follow-up from the original FCR300 study,\textsuperscript{5} and confirmed by more recent studies.\textsuperscript{6,7} FCR is particularly beneficial for the group of patients with the favourable mutated immunoglobulin heavy chain (IGHV), whereas patients with the more aggressive unmutated IGHV rarely achieve long-term remission with this regimen.

Duvelisib is an oral phosphoinositide-3-kinase (PI3K) delta/gamma inhibitor that is approved as a single agent for the treatment of patients with CLL or SLL relapsed after 2 or more prior lines of therapy. A notable aspect of duvelisib is that patients with relapsed or refractory CLL can achieve equivalent progression free survival (PFS) irrespective of whether they have high risk genetic markers.\textsuperscript{8,9} Duvelisib was recently studied in combination with bendamustine and rituximab chemoimmunotherapy in patients with relapsed or refractory CLL.\textsuperscript{10} The combination did not appear to increase toxicities beyond the known safety profile of the individual agents, and the regimen was active in this difficult to treat population.

Based on prior experience with immune-mediated toxicities and infections observed with the PI3K delta inhibitor idelalisib in a frontline CLL population,\textsuperscript{11} it has been uncertain whether any agent in the PI3Ki class could be safely administered in the frontline setting. In a phase 1 study, 18 patients with treatment-naive CLL were treated with duvelisib monotherapy and, although immune-mediated toxicities occurred, they were manageable in most cases.\textsuperscript{12} We hypothesized that combining duvelisib with FCR would mitigate immune-mediated toxicities in the frontline setting by utilizing chemoimmunotherapy to dampen the immune response, and would have the potential to induce deep remissions that could translate into a higher rate of long-term treatment-free remission than has been observed historically with FCR, particularly for patients with higher risk disease. Here, we report the results of our phase 1b/2 study of duvelisib + FCR (DFCR) as initial therapy for younger CLL patients.

**METHODS**

**Patients**

This phase 1b/2 investigator-initiated study was conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Patients aged 18 to 65 years were eligible for
study if they had a confirmed diagnosis of CLL or SLL requiring initial therapy per
International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2008 criteria, and
had an Eastern Cooperative Oncology Group performance status (PS) of 0 or 1. Acceptable
baseline laboratory values and key clinical criteria necessitated for study enrolment are
defined in the supplemental materials. The protocol was approved by the Institutional
Review Board, and all patients provided written informed consent. The study was designed
according to Good Clinical Practice guidelines and the Declaration of Helsinki and is
registered with ClinicalTrials.gov (NCT02158091).

Study Design
In the 1-week lead-in period, patients were treated with single-agent duvelisib in a standard
3+3 design at 1 of 2 dose levels (25 mg qd or 25 mg bid) for 7 days. Starting on cycle 1, day
1, fludarabine (25 mg/m², days 1–3), cyclophosphamide (250 mg/m², days 1–3), and
rituximab (375 mg/m² day 1, cycle 1; 500 mg/m² day 1 cycles 2–6) were administered with
continuous duvelisib (25 mg qd or 25 mg bid) for up to six 28-day cycles. Patients achieving
either partial response (PR) or complete response (CR) after the combination phase
continued on duvelisib maintenance (at the same dose they were previously on) for up to 2
years. Patients completing 2 years of duvelisib maintenance, and those who did not receive
maintenance, were followed on a schedule at the discretion of their physician until initiation
of new therapy or death. Patients who completed maintenance and reached an undetectable
minimal residual disease (uMRD) state had optional bone marrow (BM) biopsies yearly to
assess for conversion to MRD-positive status. Prophylaxis with granulocyte colony
stimulating factor, trimethoprim/sulfamethoxazole or equivalent, and acyclovir or equivalent
was mandatory.

Outcome Measures
In the phase 1b portion of the study, the primary objective was to assess the safety of DFCR.
Dose-limiting toxicity (DLT) was defined by any grade 3 or greater hematologic toxicity
(with exceptions for grade 3 or grade 4 neutropenia or thrombocytopenia that persisted for ≤
10 days off treatment), any grade 4 or greater elevation in ALT/AST, or grade 3 or greater
nonhematologic toxicity with the following exceptions: grade 3 or greater nausea/vomiting/
diarrhoea despite optimal supportive care that persisted for 7 days or less, grade 3 infusion
reactions, grade 3 asymptomatic laboratory abnormalities that improved to grade 2 or less
within 3 days, or inability to receive day 1 therapy of Cycle 2 even after a 3-week treatment
delay due to continued drug related toxicity from the prior cycle.

In phase 2, the primary objective was to determine the proportion of patients achieving
CR/CRi with BM-uMRD 2 months after completion of DFCR. uMRD was defined as <10⁻⁴
CLL cell frequency as measured by either 4- or 8-color flow cytometry in a centralized
laboratory. Secondary endpoints included clinical response rates (overall response rate
[ORR], CR, PR), PFS, event-free survival, remission duration, rates of best response and
best BM and peripheral blood (PB) MRD-negativity, safety/tolerability, and association of
established CLL prognostic factors (FISH cytogenetics, IGHV, TP53, and NOTCH1
mutation) with clinical response. Response by 2008 iwCLL criteria was assessed after the
first 3 cycles, 2 months after the final DFCR cycle, and every 6 months thereafter. In patients

Leukemia. Author manuscript; available in PMC 2021 April 10.
who continued duvelisib maintenance, BM-MRD was also evaluated 1 year and 2 years post-DFCR. Adverse events (AEs) were assessed using Common Terminology Criteria for Adverse Events version 4.03 and 2008 iwCLL criteria for hematologic toxicity.\textsuperscript{13}

**Statistical Analysis**

An exact 1 sample binomial test was used to compute the sample size. Twenty-six patients were needed in order to detect a 45\% rate of CR with BM-uMRD, assuming the rate for the null hypothesis is 20\% and 90\% power and 6\% 1-sided type I error. The null hypothesis would be rejected if 9 or more patients with CR with BM-uMRD were observed. Clinical response, including ORR, CR and PR rates determined by iwCLL criteria as well as rate of PB-MRD negativity, are summarized as percentages, and 95\% exact binomial CI test. The Kaplan-Meier method was used to estimate PFS and OS descriptively. Association of IGHV mutation status and clinical response was assessed using Fisher’s exact test for categorical variables and Wilcoxon’s rank sum test for continuous variables. Toxicity was reported descriptively. Efficacy and safety analyses were based on the intent-to-treat (ITT) population, which included all patients who received $\geq$1 dose of study treatment.

**RESULTS**

**Patients**

Between July 11, 2014 and August 15, 2016, 32 patients were enrolled and began DFCR treatment. The median age was 55 years (range 45–65), 22/32 (69\%) were male, and 13/32 (41\%) patients had Rai stage III or IV disease at study entry (Table 1). IGHV was unmutated in 18/32 patients (56\%). NOTCH1 was mutated in 1 patient (3\%), and 3/32 patients (9.4\%) had TP53 aberrant disease (including 1 patient (3.1\%) with deletion 17p [del(17p)] and complex karyotype and 2 patients (6\%) with TP53 mutation and intact chromosome 17).

The patient disposition for all 32 patients enrolled is summarized in Figure 1. In the phase 1b portion of the study, 6 patients were treated initially in the duvelisib 25 mg qd cohort and only 1 DLT occurred (grade 3 febrile neutropenia during cycle 1 with duvelisib successfully resumed with dose reduction). Therefore, 6 patients were subsequently accrued to a cohort treated with duvelisib 25 mg bid. No additional DLTs occurred, and thus the recommended phase 2 dose of duvelisib when given with FCR was determined to be 25 mg bid, which is the FDA-approved dose for duvelisib monotherapy. In the phase 2 portion of the study, an additional 20 patients were then accrued at this dose, for a total of 26 patients treated at duvelisib 25 mg bid (6 from phase 1b plus 20 from phase 2).

**Study Drug Exposure**

Some 13\%, 9\%, 13\%, 13\%, and 53\% of patients completed 1, 3, 4, 5, and 6 cycles of combination therapy, respectively, for a median of 5.5 (range, 1–6) cycles. Twenty-one patients (66\%) began the duvelisib monotherapy portion of the study, with 12 of these patients completing the planned 2 full years of duvelisib maintenance, and 9 patients discontinuing maintenance early due to toxicities (5 due to diarrhea or colitis, 2 due to rash, and 1 each due to prolonged neutropenia, elevated amylase/lipase). Eleven patients discontinued from the study due to toxicities prior to initiating duvelisib maintenance (5 due
Safety

All 32 patients were included in the safety analysis. Thirty of these 32 patients (94%) experienced at least one AE, of which the majority were grades 1 or 2 (Table 2). Hematologic toxicities were common and included thrombocytopenia (81%; 41% grade ≥3), neutropenia (78%; 63% grade ≥3), and lymphopenia (72%; 66% grade ≥3). The most common nonhematologic toxicities of any grade were nausea (72%), fatigue (69%) and fever (56%). Hyperglycaemia was also observed in 56%, but was all low-grade (41% grade 1, 15% grade 2) and in most cases was transient and thought to be secondary to steroid use in the context of managing immune-mediated toxicities. Seven patients (22%) experienced febrile neutropenia. In total, 3 DLTs were reported, all of which were febrile neutropenia occurring in the first cycle of combination therapy. These 3 events included the 1 patient in phase 1b with grade 3 febrile neutropenia during the first combination cycle with duvelisib at 25 mg qd and 2 patients in the phase 2 portion of the study with grade 3 (n=1) or grade 4 (n=1) neutropenia during the first combination cycle with duvelisib at 25 mg bid that persisted for >10 days despite holding duvelisib and was complicated by fever.

Toxicities believed to be immune-mediated in nature included transaminitis (34%, 28% grades 3/4), inflammatory arthritis (9%, all grade 2), colitis (6%, 1 grade 2 and 1 grade 3), and grade 2 pericarditis and pancreatitis in 1 patient each. These immune-mediated AEs occurred throughout the study, with transaminitis and arthritis being more common early on during the combination portion of the study and colitis events occurring later in patients on duvelisib monotherapy. The pericarditis and pancreatitis events also occurred later, being observed in patients who had completed the combination portion of the study and were on duvelisib maintenance. Immune-mediated AEs were generally reversed by holding duvelisib, although 14/32 (44%) patients were managed with corticosteroids at least once during the course of their treatment to manage these toxicities.

Serious AEs (SAEs) included 1 patient each with grade 3 sinusitis, grade 3 rash, and grade 2 CMV infection. Additional AEs of note that did not meet SAE criteria included grade 3 autoimmune haemolytic anaemia and grade 1 herpes zoster infection. Grade 3 or higher infection occurred in 9/32 (28%) patients. This included 6 cases of pneumonia, 3 of which were due to *Pneumocystis jiroveci* pneumonia despite prophylaxis (TMP/SMX in 1 and atovaquone in 2 patients), all 3 of which resolved with treatment. Secondary malignancies occurred in 3 patients, including 1 case each of myelodysplastic syndrome (MDS) that occurred 3 months after completing duvelisib monotherapy, a fatal glioblastoma multiforme (GBM) that occurred 3 months after completing duvelisib monotherapy, and a fatal metastatic melanoma that occurred 10 months after completing FCR in a patient who had previously discontinued duvelisib due to transaminitis. Six patients required duvelisib dose reductions: 3 due to grade 3 febrile neutropenia, and 1 each due to grade 3 lung infection, grade 3 ALT increase, and grade 2 pericarditis. Additionally, 1 patient each with grade 3 anaemia, grade 3 neutropenia, and grade 1 thrombocytopenia underwent dose reductions of both fludarabine and cyclophosphamide.
Efficacy

Response data, including BM-MRD status post-combination treatment, was available for 29 patients. All evaluable patients achieved response with CR, CR with incomplete hematologic recovery (CRi), or PR. By ITT, the ORR was 88%, with the 3 patients coming off study due to toxicity prior to a response evaluation counted as nonresponders (2 discontinued due to early transaminitis and 1 due to prolonged pancytopenia). After 3 cycles, post-final cycle of FCR, and at time of best response, CR/CRi rates among all patients in an ITT analysis were 19%, 25%, and 56%, respectively (Table 3, Figure 2A). Among patients with mutated IGHV, CR/CRi rates after 3 cycles, post-FCR, and at time of best response were 21%, 22%, and 29%, respectively (Figure 2B), while those with unmutated IGHV were similar at 17%, 22%, and 56%, respectively (Figure 2C). Although all 3 patients with TP53 aberrant disease achieved response initially, two of the three responses were PR with detectable BM-MRD with short times to progression, with one patient progressing just after completing cycle 3 of DFCR and the other progressing just after completing cycle 6 of DFCR.

The phase 2 portion of the trial did not achieve its primary endpoint, with the combined CR or CRi and BM-uMRD (CR/CRi/uMRD) rate post-DFCR of 25% (95% CI: 11–43) with a 1-sided exact binomial $P$ value of 0.3. CR/CRi/uMRD status was achieved at the end of combination treatment by 8 patients, with rates increasing over the course of combination treatment (Table 3, Figure 2A). For patients receiving the 25 mg bid duvelisib dose, the CR/CRi/uMRD rate was 6/26 (23%). The best rate of CR/CRi with uMRD was attained by 6/14 (43%) patients with mutated and 5/18 (28%) patients with unmutated IGHV. By ITT analysis, BM-uMRD was achieved by 18/32 patients (56%) at post-combination assessment, and at best response by 21/32 (66%) patients. In patients with mutated IGHV, BM-uMRD rates were 57%, 64%, and 64% after 3 cycles, post-FCR, and at best response, respectively (Figure 2B), while corresponding rates for patients with unmutated IGHV were 39%, 50%, and 67% (Figure 2C). There were no significant differences in uMRD rates between IGHV mutated and unmutated groups at any time point.

Survival and Progression

With a median follow-up of 36.3 months (range, 7–57), 3-year OS estimates by ITT are 93% (95% CI: 84–100) for the entire population (Figure 3A), and 92% (95% CI: 79–100) and 93% (95% CI: 82–100) for IGHV mutated and unmutated, respectively. Three-year PFS by ITT is 73% (95% CI: 58–93) for the entire population (Figure 3B), and 82% (95% CI: 62–100), and 66% (95% CI: 46–96) for IGHV mutated and unmutated patients, respectively. At the time of data cutoff, 6 patients had progressed, including 1 with del(11q) and unmutated IGHV who developed asymptomatic progression about 6 months after coming off of duvelisib maintenance after 16 months due to rash, but has still not required additional therapy 2.5 years after first signs of progression. In total, 3 patients have died, including the patient with Richter’s syndrome and 2 patients due to secondary malignancies (GBM and melanoma).
DISCUSSION

Patients with CLL who require initial therapy now have several different effective and well-tolerated regimens from which to choose. Older patients and those with comorbidities may be best served by novel agent monotherapy given continuously, or by intermittent dosing of time-limited, novel-agent–only combination regimens. The goal for such patients is not cure, but to control the disease for a period of several years. For younger, fit patients, the time horizon is much longer, and these patients may wish to pursue more aggressive treatment approaches with an aim to achieve cure with time-limited therapy. To build on the long-term remissions that have already been shown to be achievable with FCR, we added the potent PI3K delta/gamma inhibitor duvelisib to FCR and hypothesized that DFCR would be tolerable and induce deeper responses that could translate into prolonged survival across diverse CLL prognostic groups.

Although the rate of patients achieving CR with BM-uMRD after completing DFCR (25%) is not significantly higher than the 20% rate expected with FCR alone, the rate of BM-uMRD irrespective of iwCLL response is higher than would be expected with FCR alone at 56% at the end of combination therapy, and rises further to 66% as best response after duvelisib maintenance. This discrepancy between rates of CR with BM-uMRD and BM-uMRD alone is due to several patients who achieved BM-uMRD but still had residual lymphadenopathy <2.5 cm in long axis. Recent analyses of studies of both frontline FCR alone and novel-agent–based approaches such as venetoclax plus obinutuzumab have suggested that MRD status is a better predictor of PFS and OS than iwCLL response. These studies demonstrated that patients in PR with uMRD have similar survival as patients in CR with uMRD and improved survival compared to patients in CR with detectable MRD. Thus, the high rates of BM-uMRD observed with DFCR might be expected to confer long PFS. Although the follow-up for this frontline study is still relatively short, the 3-year PFS by ITT was 73% (95% CI: 58–93), which is similar to what has been observed with FCR alone in recent studies, where 3-year PFS ranged from ~70–73% (although notably these other trials excluded patients with del(17p). One important difference in the patient population of this current study is that we included 3 patients with TP53 aberrant disease, whereas other recent studies including FCR excluded such patients. Moreover, several of the patients on our study needed to discontinue DFCR due to toxicity and thereafter experienced disease progression off therapy. Longer term follow-up will be needed to better understand whether the high rate of undetectable MRD achieved with DFCR will translate into prolonged PFS beyond what would be expected from FCR alone.

Importantly, our study allowed patients from all genetic risk groups, including those with a variety of FISH cytogenetic abnormalities, somatic mutations, and a mix of mutated and unmutated IGHV. Historically, patients with unmutated IGHV rarely achieve long-term PFS with FCR alone. Thus, an important secondary endpoint of the DFCR study was to assess outcomes by IGHV status. In patients with mutated and unmutated IGHV, best BM-uMRD rates were 64% and 67%, respectively. To date, this has translated into roughly equivalent PFS, with 3-year ITT PFS of 82% (95% CI: 62–100), and 66% (95% CI: 46–96) for IGHV mutated and unmutated patients, respectively. Additional follow-up will be needed to know whether equivalent PFS between these 2 groups will be achieved in the long term with this

Leukemia. Author manuscript; available in PMC 2021 April 10.
time-limited FCR-based regimen. Although all 3 of the patients with TP53-aberrant CLL derived clinical benefit from DFCR, 2 of these patients have already progressed including one with Richter’s syndrome, and given the variety of active novel-agent-only regimens now available for such patients, our data do not support DFCR as a preferred option for such patients.

The toxicities observed with DFCR included AEs typically observed with duvelisib and FCR individually. For example, the proportion of patients with cytopenias are in a similar range as reported in prior studies of FCR alone, although even with mandatory G-CSF, the rate of febrile neutropenia was 22%. Immune-mediated AEs were relatively common and required active management. Although the rates of grade 3 or higher transaminitis were relatively high at 28%, this rate does compare favourably to the even higher rates that have been observed when initiating PI3K-inhibitor monotherapy with idelalisib in the frontline setting, where rates as high as 54% have been reported. Several patients on DFCR also experienced diarrhea and colitis, a known toxicity with PI3K-inhibitors, as well as inflammatory arthritis, which has not commonly been described with this class of drugs. These immune-mediated AEs were generally responsive to drug holds and corticosteroid treatment, but sometimes did require prolonged intervention prior to resolution. Despite mandatory growth factor support and antimicrobial prophylaxis, infectious complications were also fairly common on this study, and opportunistic infections including Pneumocystis jiroveci pneumonia and a case of CMV reactivation were observed, highlighting the need for careful management of patients on DFCR. Three patients on this study developed significant secondary cancers, which in two cases were fatal. These cases are consistent with the increased risk of secondary malignancies in patients with CLL, perhaps particularly those on therapy including FCR.

A limitation of our study is the relatively small sample size, which makes it challenging to identify a particular subgroup who may benefit most from this regimen and, conversely, to identify patients who may be at particular risk of immune-mediated or infectious AEs. As our study required patients to complete up to 6 cycles of FCR if tolerated, we also do not know whether some patients may have derived similar efficacy with less toxicity with fewer cycles of FCR, as has been suggested by prior retrospective studies of FCR alone. As a single-arm study, we also cannot know how DFCR compares to other promising frontline novel agent plus chemoimmunotherapy regimens such as ibrutinib + FCR or ibrutinib + FC + obinutuzumab. Unlike ibrutinib-based regimens, DFCR was not associated with any significant cardiovascular toxicity or bleeding risk. As such, for patients with those comorbidities (including patients on anticoagulation) who are considering a kinase inhibitor plus FCR-based approach to initial therapy, DFCR could be an option to consider.

In summary, our phase 1b/2 study identified a recommended phase 2 dose of duvelisib of 25 mg bid when given in combination with FCR in younger CLL patients receiving frontline therapy. We observed deep responses, including achievement of BM-uMRD in about two-thirds of patients, irrespective of IGHV mutation status; however, while the regimen is certainly active, the 3-year PFS of 73% does not appear significantly superior to historical results with FCR alone. Immune-mediated toxicities and infectious complications were relatively common, but with active intervention were manageable for most patients. If DFCR
were to be studied further, strategies that include a shorter course of FCR and other approaches to mitigate toxicity while maintaining efficacy would need to be explored.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

All authors wish to thank the patients and their families for participating in the study. We also thank Infinity Pharmaceuticals, in particular Julian Adams, PhD and David Roth, MD for initial support of the study, as well as Robert Forrester and David Weaver, PhD for initial support of the study at Verastem, Needham, MA. Dr. Davids acknowledges a Career Development Award from the American Society of Clinical Oncology and the Leukemia & Lymphoma Society for his Scholar in Clinical Research Award. Dr. Brown acknowledges support from NCI R01 CA213442-01A1. Limited medical writing support for this paper was provided by Bio Connections LLC, and the authors would like to particularly thank Devon Roll, PhD and Emily Hale. Verastem Oncology provided funding for research and medical writing; however, authors had final authority on content and selection of journal.

Competing Interests

MSD has received grants from Acerta Pharma, BMS, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem, and consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, AstraZeneca, Beigene, Celgene, Genentech, Gilead Sciences, Infinity Pharmaceuticals, Janssen, Loxo, MEI Pharma, Merck, Pharmacyclics, Sunesis, Syros Pharmaceuticals, TG Therapeutics, and Verastem; DCF received consulting fees from Merck, Kite, and Gilead; KF is an employee of Verastem; JM received consulting fees from Janssen Pharmaceuticals, and AstraZeneca; PA received consulting fees from Merck, BMS, Infinity, Pfizer, Affirmed, and Adaptive, and research funding from Merck, BMS, Affirmed, Adaptive, Roche, Tensha, Otsuka, and Sigma Tau; JA served on the scientific advisory board for Janssen, Kite Pharma, AbbVie, Karyopharm, Bayer, Gilead, Verastem, Merck, Novartis, Juno, Amgen, Celgene, Genentech, and Seattle Genetics; JRB received consulting fees from AbbVie, Acerta, Astellas, AstraZeneca, Beigene, Celgene, Genentech/Roche, Gilead, Invycts, Janssen, Kite, Loxo, Morphosys, Novartis, Pfizer, Pharmacyclics, Rectx, Sun, Sunesis, Teva, TG Therapeutics, Verastem and Novartis; grants from Gilead, Pfizer, Loxo, Sun and Verastem; and served on the Data Safety Monitoring Boards for Morphosys and Invycts. ST, MM, JH, and OO have nothing to disclose.

References

1. Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. The New England journal of medicine. 2019;381(5):432–443. [PubMed: 31365801]
2. Sharman JP, Banerji V, Fogliatto LM, Herishanu Y, Munir T, Walewska R, et al. ELEV ATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL). Blood. 2019;134(Supplement_1):31–31.
3. Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet (London, England). 2020;395(10232):1278–1291.
4. Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. The New England journal of medicine. 2019;380(23):2225–2236. [PubMed: 31166681]
5. Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukaemia. Blood. 2016;127(3):303–309. [PubMed: 26492934]
6. Fischer K, Bahlo J, Fink AM, Goede V, Herling CD, Cramer P, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127(2):208–215. [PubMed: 26486789]
7. Rossi D, Terzi-di-Bergamo L, De Paoli L, Cerri M, Ghilardi G, Chiarenza A et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126(16):1921–1924. [PubMed: 26276669]

8. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illes A, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–2455. [PubMed: 30287523]

9. Davids MS, Kuss BJ, Hillmen P, Montillo M, Moren C, Essell J, et al. Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020.

10. Flinn IW, Cherry MA, Maris MB, Matous JV, Berdeja JG, Patel M. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. American journal of hematology. 2019;94(12):1325–1334. [PubMed: 31490009]

11. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, et al. Idelalisib given frontline for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128(2):195–203. [PubMed: 27247136]

12. O’Brien S, Patel M, Kahl BS, Horwitz SM, Foss FM, Porcu P, et al. Duvelisib, an oral dual PI3K-delta,gamma inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American journal of hematology. 2018;93(11):1318–1326. [PubMed: 30094870]

13. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. [PubMed: 18216293]

14. Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(9):980–988. [PubMed: 22331940]

15. Kovacs G, Robrecht S, Fink AM, Bahlo J, Cramer P, von Tresckow J, et al. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(31):3758–3765. [PubMed: 27573660]

16. Fischer K, Ritgen M, Al-Sawaf O, Robrecht S, Tandon M, Fink AM, et al. Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood. 2019;134(Supplement_1):36–36.

17. Kutsch N, Bahlo J, Robrecht S, Franklin J, Zhang C, Maurer C, et al. Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). HemaSphere. 2020;4(1):e336. [PubMed: 32072150]

18. Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 2016;17(7):928–942. [PubMed: 27216274]

19. Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727–3732. [PubMed: 24705492]

20. Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. The Lancet Haematology. 2019;6(8):e419–e428. [PubMed: 31208944]

Leukemia. Author manuscript; available in PMC 2021 April 10.
21. Michallet AS, Dilhuydy MS, Subtil F, Rouille V, Mahe B, Laribi K, et al. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. The Lancet Haematology. 2019;6(9):e470–e479. [PubMed: 31324600]

22. Jain N, Thompson PA, Burger JA, Ferrajoli A, Takahashi K, Estrov ZE, et al. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53. Blood. 2019;134(Supplement_1):357–357.
Figure 1.
Patient Disposition
Figure 2: Complete Response (CR) or CR With Incomplete Count Recovery (CRi) and Undetectable Minimal Residual Disease (BM-uMRD) by Assessment.
(A) All patients. (B) Patients with mutated immunoglobulin heavy-chain variable region (IGHV). (C) Patients with unmutated IGHV. FCR, fludarabine, cyclophosphamide, plus rituximab.
Figure 3:
Overall (A) and Progression-Free Survival (B) for the Entire Study Population by ITT Analysis
Table 1.

Baseline Characteristics

|                          | Dose Level 1          | Dose Level 2          | Total     |
|--------------------------|-----------------------|-----------------------|-----------|
|                          | (Duvelisib 25 mg qd)  | (Duvelisib 25 mg bid) |           |
|                          | N=6                   | N=26                  | N=32      |
| Median age (IQR), years  | 55 (52–58)            | 55 (52–59)            | 55 (52–59)|
| Men, n (%)               | 5 (83)                | 17 (65)               | 22 (69)   |
| Women, n (%)             | 1 (17)                | 9 (35)                | 10 (31)   |
| ECOG performance status, n (%) |             |                       |           |
| 0                        | 2 (33)                | 12 (46)               | 14 (44)   |
| 1                        | 4 (67)                | 14 (54)               | 18 (56)   |
| Rai stage, n (%)         |                       |                       |           |
| 0                        | 3 (50)                | 4 (15)                | 7 (22)    |
| 1                        | 2 (33)                | 7 (27)                | 9 (28)    |
| 2                        | 1 (17)                | 2 (8)                 | 3 (9)     |
| 3                        | 0 (0)                 | 2 (8)                 | 2 (6)     |
| 4                        | 0 (0)                 | 11 (42)               | 11 (34)   |
| Median WBC (IQR), × 10⁹/L| 79 (51–120)           | 97 (20–182)           | 97 (31–168) |
| Median hemoglobin (IQR), g/dL | 12 (11–14)            | 10 (10–12)            | 11 (10–13) |
| Median hematocrit (IQR), % | 37 (34–41)            | 33 (29–39)            | 34 (30–39) |
| Median platelets (IQR), × 10⁹/L | 136 (89–180)          | 110 (89–156)          | 115 (88–157) |
| Median BM involvement (IQR), % | 90 (68–90)            | 80 (70–90)            | 80 (68–90) |
| Median IgG (IQR), mg/dL  | 733 (632–794)         | 835 (498–958)         | 789 (527–955) |
| Median IgA (IQR), mg/dL  | 73 (67–94)            | 83 (64–145)           | 79 (66–125) |
| Median β₂-microglobulin (IQR), mg/L | 2.9 (2.875–3)         | 4 (4–6)               | 4 (4–6)   |
| IGHV unmutated           | 4/6 (67)              | 14/26 (54)            | 18/32 (56) |
| ZAP-70 positive          | 2/6 (33)              | 17/25 (68)            | 19/31 (61) |
| Del(13q)                 | 2/6 (33)              | 12/23 (52)            | 14/29 (48) |
| Del(11q)                 | 2/6 (33)              | 6/24 (25)             | 8/30 (27) |
| Trisomy 12               | 1/66 (17)             | 6/25 (24)             | 7/31 (23) |
| Del(17p)                 | 0 (0)                 | 2/24 (8)              | 2/30 (7)  |
| 6q detected              | 0 (0)                 | 3/13 (23)             | 3/19 (16) |
| t(14;18)                 | 0 (0)                 | 1/14 (7)              | 1/20 (5)  |
| Normal FISH              | 2/6 (33)              | 4/26 (15)             | 6/32 (19) |
| TP53 mutation            | 0 (0)                 | 4/26 (15)             | 4/32 (13) |
| NOTCH1 mutation          | 0 (0)                 | 1/26 (4)              | 1/32 (3)  |
| MYD88 mutation           | 0 (0)                 | 1/24 (4)              | 1/24 (4)  |
### Table 2:

All-Grade, All-Causality TEAEs in ≥10% of Patients and Grade ≥3 Events in All Patients

|                  | Grades 1–2, n (%) | Grade 3, n (%) | Grade 4, n (%) | Grade 5, n (%) | Total N (%) |
|------------------|-------------------|----------------|----------------|----------------|-------------|
|                  | n (%)             | n (%)          | n (%)          | n (%)          | N (%)       |
| Hematologic      |                   |                |                |                |             |
| Decreased platelet count | 13 (41)         | 2 (6)          | 11 (34)        | 0 (0)          | 26 (81)     |
| Decreased neutrophil count | 5 (16)          | 1 (3)          | 19 (59)        | 0 (0)          | 26 (78)     |
| Decreased lymphocyte count | 2 (6)           | 6 (19)         | 15 (47)        | 0 (0)          | 23 (72)     |
| Decreased WBC count | 6 (19)           | 7 (22)         | 9 (28)         | 0 (0)          | 22 (69)     |
| Anemia           | 12 (38)           | 5 (16)         | 0 (0)          | 0 (0)          | 17 (53)     |
| Febrile neutropenia | 0 (0)            | 7 (22)         | 0 (0)          | 0 (0)          | 7 (22)      |
| Increased lymphocyte count | 3 (9)           | 1 (3)          | 0 (0)          | 0 (0)          | 4 (12)      |
| Nonhematologic   |                   |                |                |                |             |
| Nausea           | 23 (72)           | 0 (0)          | 0 (0)          | 0 (0)          | 23 (72)     |
| Fatigue          | 21 (66)           | 1 (3)          | 0 (0)          | 0 (0)          | 22 (69)     |
| Fever            | 18 (56)           | 0 (0)          | 0 (0)          | 0 (0)          | 18 (56)     |
| Hyperglycemia    | 18 (56)           | 0 (0)          | 0 (0)          | 0 (0)          | 18 (56)     |
| Diarrhea         | 15 (47)           | 1 (3)          | 0 (0)          | 0 (0)          | 16 (50)     |
| ALT increased    | 6 (19)            | 5 (16)         | 4 (13)         | 0 (0)          | 15 (47)     |
| AST increased    | 7 (22)            | 7 (22)         | 1 (3)          | 0 (0)          | 15 (47)     |
| Cough            | 13 (41)           | 0 (0)          | 0 (0)          | 0 (0)          | 13 (41)     |
| Skin disorders   | 12 (38)           | 1 (3)          | 0 (0)          | 0 (0)          | 13 (41)     |
| Anorexia         | 11 (34)           | 0 (0)          | 0 (0)          | 0 (0)          | 11 (34)     |
| Dyspnea          | 11 (34)           | 0 (0)          | 0 (0)          | 0 (0)          | 11 (34)     |
| GI disorders     | 10 (31)           | 1 (3)          | 0 (0)          | 0 (0)          | 11 (34)     |
| Upper respiratory tract infection | 11 (34)      | 0 (0)          | 0 (0)          | 0 (0)          | 11 (34)     |
Table 3:
Response, Bone Marrow MRD, and Combined Response/Bone Marrow MRD by Assessment

| Best Response          | Cycle 3 (N=32) | Post-DFCR (N=32) | Best Response (N=32) |
|------------------------|----------------|------------------|----------------------|
| CR/CRi                 | 6 (19)         | 8 (25)           | 18 (56)              |
| PR                     | 23 (72)        | 21 (66)          | 10 (31)              |
| CR or CRi or PR        | 29 (91)        | 29 (91)          | 28 (88)              |
| NE*                   | 3 (9)          | 3 (9)            | 3 (9)                |
| BM-MRD−                | 15 (47)        | 18 (56)          | 21 (66)              |
| BM-MRD+                | 13 (41)        | 10 (31)          | 7 (22)               |
| BM-MRD UNK             | 4 (13)         | 4 (13)           | 4 (13)               |
| CR/CRi/MRD−            | 4 (13)         | 8 (25)           | NA‡                  |
| CR/CRi/MRD+            | 2 (6)          | -                | NA‡                  |
| PR/MRD−                | 11 (34)        | 10 (31)          | NA‡                  |
| PR/MRD+                | 11 (34)        | 10 (31)          | NA‡                  |

*NE: 3 patients were not evaluable for efficacy due to early discontinuation because of toxicity

‡Because of optional sampling times and missing MRD data at some time points, the best responses in these categories cannot be defined and are listed as NA.